<DOC>
	<DOCNO>NCT00478465</DOCNO>
	<brief_summary>The purpose study determine whether drug valganciclovir significant real benefit central core symptom experience patient high titer EBV HHV-6 experience long-standing fatigue cognitive impairment ( CFS ) . In addition , characterize quantifiable biological marker patient facilitate identification likely respond valganciclovir make possible assess response treatment .</brief_summary>
	<brief_title>Valganciclovir ( Valcyte ) Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 ( HHV-6 ) Epstein-Barr Virus ( EBV )</brief_title>
	<detailed_description>Chronic fatigue syndrome ( CFS ) clinically define condition characterize severe disable fatigue combination symptom prominently feature self-reported impairment concentration short-term memory , sleep disturbance , musculoskeletal pain . Prevalence CFS adult population estimate 0.007 % 2.8 % . No pathognomonic sign diagnostic test condition yet validate scientific study ; addition , definitive treatment clinically available . Suggested etiology CFS include , limited : viral bacterial infection , endocrine-metabolic dysfunction , immunological imbalance , neurally-mediated hypotension depressioN . EBV HHV-6 among virus frequently think associate CFS . We recently encounter group patient Stanford chronically infect human herpes virus 6 ( HHV-6 ) Epstein-Barr virus ( EBV ) , suffer debilitate fatigue least one year experience significant improvement fatigue cognitive symptom follow administration valganciclovir . Their antibody titer virus high ( median antibody titer EBV viral capsid antigen 1:2560 HHV-6 IgG 1:1280 ) despite fact know infected EBV HHV-6 several year . We suspect symptom could result immune dysregulation trigger high level replication EBV HHV-6 ( alteration immune system aberrant cytokine profile propose central abnormality patient CFS associate virus parvovirus B19 . At time , familiar use valganciclovir context several clinical setting include known indication reactivation viral infection immunocompromised patient . We comfortable use valganciclovir ( 900 mg bid three week follow 900 mg qd complete 3 12 month treatment ) patient solid bone marrow transplant , cancer immunosuppressive disorder develop CMV , EBV , HHV-6 disease . We hypothesize long course ( i.e . 6 month ) valganciclovir could effectively decrease stop ongoing viral replication EBV HHV-6 virological effect could translate clinical laboratory benefit ( i.e . decrease resolution lymphadenopathy , reversion CD4/CD8 ratio abnormality ) . We surprise see dramatic recovery level physical activity also observe Stanford patient ( median 10 % energy level daily activity baseline 90 % valganciclovir use ) . Of note , drug also try patient improvement level physical activity observe . The total number patient treat today 30 , 26 `` elevate titer '' 4 `` low titer '' . Of 26 patient `` elevated titer '' , 25 dramatic recovery . Of 4 patient `` low titer '' , none respond . We believe successful experience valganciclovir subset patient CFS Stanford call prospective study exclude placebo effect . We propose measure viral , immunologic , genomic endpoint ass whether objective measurable change parameter whether correlate clinical improvement . Clinical improvement assess objective measurement daily physical psychological activity . This help elucidate possible role HHV-6 , EBV ( yet know virus ) and/or alter immune system trigger symptom experience patient suffer CFS establish whether drug valganciclovir reverse abnormality . This study may also shed light biomarker profile biomarkers associate ( diagnostic ) CFS . We execute randomize , double-blind , placebo-controlled clinical trial evaluate efficacy safety valganciclovir patient experience chronic fatigue syndrome elevate antibody titre Human Herpesvirus-6 ( HHV-6 ) Epstein-Barr Virus ( EBV ) Objectives 1 . To determine whether drug valganciclovir significant real benefit central core symptom experience patient high titer EBV HHV-6 experience long-standing fatigue cognitive impairment ( CFS ) . 2 . To characterize quantifiable biological marker patient facilitate identification likely respond valganciclovir make possible assess response treatment . Design study A double-blind , placebo-controlled , randomized clinical trial . All patient give active drug ( 20 patient ) placebo ( 10 patient ) 6 month follow additional 3 month . Patients placebo arm take valganciclovir look-alike tablet contain active drug initial six month period . Subsequently patient offer 6 month trial valganciclovir end study ( last enrol patient reach 9 month initiate therapy ) clear benefit valganciclovir therapy patient spontaneously improve . Kogelnik A , Rosso F , Hoegh-Petersen M Montoya JG . Use Valganciclovir Patients Chronically Co-infected Human Herpes Virus 6 ( HHV-6 ) Epstein-Barr Virus ( EBV ) Experiencing Long-standing Fatigue . J Clin Virol 2006 Volume 37 , Supplement 1 S33-S38 Kerr JR , Cunniffe VS , Kelleher P , Bernstein RM Bruce IN . Successful intravenous immunoglobulin therapy 3 case parvovirus B19-associated chronic fatigue syndrome . Clin Infect Dis 2003 ; 36 : e100-6</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Fatigue Syndrome , Chronic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>1 . Adult patient ( ≥ 18 year old ) . 2 . Patient understands sign Informed Consent . 3 . Patients meet clinical criterion diagnosis chronic fatigue syndrome establish International Chronic Fatigue Syndrome Study Group 1994 [ 10 ] . 4 . Patients `` viral onset '' CFS . 5 . Patients whose CFS symptoms spontaneously improve plateau least 6 month . 6 . Patients `` high '' antibody titer HHV6 IgG ≥ 640 , EBV VCA IgG ≥ 640 detectable EA Ab 1:160 HHV6 IgG ≥ 320 EBV VCA IgG ≥ 1280 detectable EA Ab 1:160 ( measure average minimum two time point obtain screen least 3 week apart ) . 7 . Patient agrees utilize two reliable method contraception combine throughout study period 90 day follow discontinuation Study Drug . 8 . Females childbearing potential negative pregnancy test screening . 1 . Patients find alternate medical and/or psychiatric cause fatigue ( see guideline establish International Chronic Fatigue Syndrome Study Group 1994 [ 1 ] . 2 . Patients history major depression psychotic melancholic feature diagnosis CFS find actively depress ( major depression psychotic melancholic feature ) depression instrument use study medical evaluation psychiatrist . 3 . Patients serious comorbidities accord investigator may interfere ability patient participate study 4 . Patients history substance abuse past year ( exclude nicotine caffeine ) positive urine test substance abuse . 5 . Patients know chronic viral orbacterial infection treatment ( ) ( ) available 6 . Patients active concurrent acute infection 7 . Patients abnormal creatinine clearance ( ≤60ml/min ) 8 . Patients ANC ≤1500 /mm3 9 . Patients Hb ≤ 10 g/dl 10 . Patients platelet count ≤ 100 000/mm3 11 . Previous hypersensitivity contraindication Valganciclovir/ganciclovir 12 . Patients take antiviral medication receive antiviral medication within previous three month 13 . Patients receive experimental therapy 14 . Patient simultaneously participate another clinical trial 15 . Patient require use prohibit concomitant medication ( see Insert VALCYTE prescribe information ) . 16 . Women childbearing age consider get pregnant study period 17 . Patient lactate female discontinue nurse prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>chronic fatigue syndrome</keyword>
	<keyword>fatigue</keyword>
	<keyword>valganciclovir</keyword>
	<keyword>valcyte</keyword>
	<keyword>Epstein-Barr virus</keyword>
	<keyword>EBV</keyword>
	<keyword>Human herpes virus 6</keyword>
	<keyword>HHV 6</keyword>
	<keyword>herpes virus</keyword>
	<keyword>herpes</keyword>
</DOC>